Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-24

FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application for levetiracetam, a generic anti-seizure medication, from BluePoint Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)